Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
73.99
-2.40 (-3.14%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Lawrence Klein |
Contact Details
Address: 855 Oak Grove Avenue, Suite 100 Menlo Park, California 94025 United States | |
| Phone | 650 606 7910 |
| Website | orukatx.com |
Stock Details
| Ticker Symbol | ORKA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000907654 |
| CUSIP Number | 687604108 |
| ISIN Number | US6876041087 |
| Employer ID | 36-3855489 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence Otto Klein Ph.D. | President, Chief Executive Officer and Director |
| Paul T. Quinlan | General Counsel and Secretary |
| Dr. Joana Goncalves M.D. | Chief Medical Officer |
| Laura Sandler | Chief Operating Officer |
| Alan Lada | Vice President of IR and Capital Markets |
| Christopher Finch | Senior Vice President and Head of Business Development and Strategy |
| Dr. Rajiv Panwar | Senior Vice President and Head of Chemistry, Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | 424B5 | Filing |
| Apr 27, 2026 | 424B5 | Filing |
| Apr 27, 2026 | 8-K | Current Report |
| Apr 21, 2026 | 424B7 | Filing |
| Apr 17, 2026 | ARS | Filing |
| Apr 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2026 | 144 | Filing |
| Apr 10, 2026 | EFFECT | Notice of Effectiveness |
| Apr 2, 2026 | S-3 | Registration statement under Securities Act of 1933 |